首页> 外文期刊>Journal of managed care pharmacy : >The U.S. food and drug administration: Drug information resource for formulary recommendations
【24h】

The U.S. food and drug administration: Drug information resource for formulary recommendations

机译:美国食品药品监督管理局:药物信息资源以供配方建议

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The U.S. Food and Drug Administration (FDA) is the regulatory agency responsible for approving all pharmaceutical products marketed in the United States. While the FDA does not conduct research for developing pharmaceutical products, the agency does review all of the scientific evidence that a pharmaceutical sponsor submits and ensures that it demonstrates U.S. regulatory standards for the product and meets approval requirements. Objectives: To provide insights, for the managed care pharmacist, into the agency's decision-making process and into the recommendations for appropriate usage and regulatory recommendations for risk mitigation by pharmaceutical sponsors. Methods: The FDA website contains a vast amount of clinically useful and meaningful information. This review focused on specific topics within the website that can be useful for the managed care pharmacist, including the following: (a) the FDA's review and evaluation of new drug applications (NDA), supplemental new drug applications (s-NDA), and biological new drug applications (BLA); (b) materials regarding a therapeutic product presented to a public FDA advisory committee meeting; and (c) the postmarket requirements and commitments database that provides information on the studies that a sponsor must conduct to maintain a product's approval for marketing in the United States. Results: This review examined the drug information contained on the FDA's website and summarized the FDA's medical and technical review, analysis and decision processes. Detailed drug information provided to the FDA by the pharmaceutical sponsor demonstrating a product's efficacy and safety is publically available upon the product's approval. Conclusion: For the managed care pharmacist involved with formulary review and recommendations, the FDA's website contains information that is available to provide insight into the agency's evaluation process and decision making for marketed pharmaceutical products. Use of these materials and understanding the regulatory context under which medical products are reviewed and approved may assist managed care pharmacists in making informed recommendations for use of the products within the context of their health systems.
机译:背景:美国食品药品监督管理局(FDA)是负责批准在美国销售的所有药品的监管机构。尽管FDA不进行药品开发研究,但该机构会审查药品赞助商提交的所有科学证据,并确保其证明该产品的美国监管标准并满足批准要求。目标:为管理式护理药剂师提供有关机构决策过程以及适当使用的建议以及减轻药品保荐人风险的监管建议的见解。方法:FDA网站包含大量临床有用和有意义的信息。此次审查的重点是网站上对管理型护理药剂师有用的特定主题,其中包括:(a)FDA对新药申请(NDA),补充新药申请(s-NDA)的审查和评估,以及生物新药应用(BLA); (b)提交给FDA咨询委员会公开会议的有关治疗产品的材料; (c)上市后要求和承诺数据库,该数据库提供有关发起人必须进行的研究以保持产品在美国的上市许可的信息。结果:该审查检查了FDA网站上包含的药物信息,并总结了FDA的医学和技术审查,分析和决策程序。由药品赞助商提供给FDA的详细药品信息,证明产品的功效和安全性,只要产品获得批准即可公开获得。结论:对于参与配方审查和建议的管理式护理药剂师,FDA网站包含可用于深入了解该机构对上市药品的评估过程和决策的信息。这些材料的使用以及对医疗产品审查和批准所依据的法规环境的了解,可以帮助管理护理药剂师针对他们的医疗系统在使用该产品时提出明智的建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号